Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:03:24.978Z.
Calculation as of: 2026-10-06T18:03:24.978Z.
Quote observation: 2026-10-06T17:55:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0a8ac43d83dffe882666147bba78c75a2aa07862642b14baa2694f769a95b4c3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Lunai Bioworks Inc.
Market Cap
$5.21M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.21M | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.20M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.35M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.88M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.02M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
